Corpus ID: 6088214

Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition.

  title={Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition.},
  author={Thorir D. Bjornsson and D. E. Schneider and Ann Hecht},
  journal={The Journal of pharmacology and experimental therapeutics},
  volume={245 3},
This investigation compares the anticoagulant activities and in vivo disposition characteristics of N-deacetylated heparin and N-desulfated heparin with those of standard heparin in an animal model. The N-deacetylated heparin retained 23% of the anticoagulant activity, 34% of the anti-Xa activity and 23% of the anti-IIa activity of standard heparin, whereas the N-desulfated heparin retained only 1.5% of the anticoagulant activity, 0.095% of the anti-Xa activity and 0.92% of the anti-IIa… Expand
N-desulfated heparin improves concanavalin A-induced liver injury partly through inhibiting T lymphocyte adhesion
N-desulfated heparin may improve immunological liver injury partly via reducing the functions, such as the adhesion to ECM, of T lymphocytes. Expand
N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo
The N-desulfated heparin has the lowest anticoagulant activity among LMWH and chemically modifiedHeparin derivatives, while preserving a potent anti-inflammatory activity, and these combined properties appear to suggest it as a safer medicine for treatment of inflammation. Expand
Anti-angiogenic poly-L-lysine dendrimer binds heparin and neutralizes its activity.
Measurement of [(3)H]-heparin confirmed stably the formation of dendriplexes, which could be essential in developing novel dendrimer-based anti-angiogenic therapeutics suitable in combinatory therapeutics and theranostics. Expand
The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins.
This review revisits past and current strategies intended to identify alternative routes of administration for unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) and embraces a more systemic approach taking into account recent advances in genomics/proteomics and nanotechnology. Expand
Pharmacologic Studies on Synthetic Analogues of Heparin with Selective Affinity to Endogenous Serine Protease Inhibitors
Walter Jeske Loyola University Chicago Heparin is a mixture of glycosaminoglycan chains which is used to prevent thrombosis in a number of clinical indications. Heparin is known to promote theExpand
Effect of N-desulfated heparin on hepatic/renal ischemia reperfusion injury in rats.
The N-desulfated heparin might prevent hepatic/renal damage induced by ischemia and reperfusion injury without significant anticoagulant activity. Expand
Heparin Pharmacokinetics and Pharmacodynamics
Both forms of heparin are useful antithrombotic agents; however, the correlation between the antithROMbotic effect and an in vitro laboratory test for either type still needs further clarification. Expand
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Three addi- tional parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to hep- arin in patients with HIT and fonda- parinux-associated HIT or osteoporosis is unlikely to occur. Expand
Heparin Binds to Lipopolysaccharide (LPS)-Binding Protein, Facilitates the Transfer of LPS to CD14, and Enhances LPS-Induced Activation of Peripheral Blood Monocytes1
It is shown that clinically used heparin preparations significantly enhance the ability of LBP to catalytically disaggregate and transfer LPS to CD14, the LPS receptor, and this novel anticoagulant drug is a potential candidate for safe administration to patients who have endotoxemia and require antICOagulation. Expand
Heparin-stimulated expression of extracellular-superoxide dismutase in human fibroblasts.
The enhanced expression of EC-SOD by heparin must contribute to the antiatherosclerotic effect of heparIn, which is measured after treatment with hepar in order to understand the role ofheparin in the anti Atherosclerotics response of fibroblasts. Expand